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Inhibition of α-glucosidase and hypoglycemic activity are two effects commonly used to identify bioactive 
compounds with potential to treat diabetes. The objectives of this study were to analyse and compare the bioactive 
compounds and α-glucosidase inhibitory effect of four different types of Swietenia mahagoni seed extract, and to 
analyse the hypoglycemic activity of the greatest inhibition of α-glucosidase-extract in rats. The extracts were obtained 
using two different solvents (aqueous and ethanol) and two different methods: maceration and reflux methods. This 
resulted in four types of extract varying by solvent and extraction method.  Testing of these extracts for α-glucosidase 
inhibitory effect was carried out in vitro using spectrophotometer. Testing for hypoglycemic activity was carried out 
in vivo using rats. A total of 40 male Sprague-Dawley rats were divided into eight groups: (1) the negative control 
group, received an oral dose of aquadest only, (2) the positive control group, was given 90% sucrose orally without S. 
mahagoni seed extract, and five treated groups (3-7), were given 90% sucrose followed by the best extract-ethanolic 
S. mahagoni seed extract in doses of 100, 200, 300, 400, and 500 mg/kgBW, and (8) the acarbose group, was given 
90% sucrose orally followed by acarbose. Glucose levels in each animal were measured at 0, 30, 60, 90, and 120 min 
after treatment. The results showed the greatest inhibition of α-glucosidase in ethanolic extract, using maceration 
methods. This ethanolic-maceration S. mahagoni seed extract also showed hypoglycemic effects in hyperglycemic 
rats at dose from 100 to 500 mg/kgBW. Ethanolic extract of S. mahagoni seed, using maceration method, can be 
proposed as potential antidiabetic agent.
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INTRODUCTION
 Diabetes mellitus (DM) is a metabolic disease 
caused by an absolute or relative lack of insulin 
secretion, low insulin sensitivity, or both. Insulin 
is needed to uptake glucose from blood circulation 
into the cells. DM interferes with this process, 
causing impairment of carbohydrate, protein and 
lipid metabolism. This disease characterized by 
abnormally high plasma glucose levels, leading to 
major complications, such as neuropathy, retinopathy, 
and cardiovascular disease. Effective control of blood 
glucose levels is key for preventing or reversing 
diabetic complications and improving the quality of 
life for diabetic patients (Bell 2001).
 The number of DM patients increases every year. 
The number of diabetics in Indonesia is expected 
to increase from 8.4 million people in 2000 to 21.3 
million in 2030 (IDF 2013). According to the World 
Health Organization (WHO), Indonesia ranks 4th 
highest in the world in number of DM patients, 
after China, India, and the United States of America 
(USA).
 DM is also a disease found in pet animals, 
especially dogs and cats (Rand & Marshall 2005; 
Wiedmeyer & DeClue 2011). The number of 
pets diagnosed also increases every year. Becker 
(2010) reported that there are more than 1.4 million 
diabetic dogs and cats in the USA with high of blood 
glucose levels (http://healthypets.mercola.com/sites/
healthypets/archive). Diabetes rates in dogs increased 
200% over a 30 year period (http://sciencedaily.com/ 
releases/2011/04/1104251). This same trend holds 
true in Indonesia, where rates of DM in pets (dogs 
and cats) increase every year. Diabetes in dogs and 
cats is usually traced to predisposing factors such as 
obesity, or inflammation of the pancreas. DM may 
also be caused by treatment with glucocorticoids 
which can disturb insulin function. In pets, DM used 
to be seen mainly in older animals, but recently has 
been on the rise in relatively young animals as well. 
DM occurs predominantly in female dogs and male 
cats (Washington State University 2013: http://www.
vetmed.wsu.edu/cliented/diabetes.aspx).
 In order to address the problem of diabetes 
mellitus in both human and animals, it is important 
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to search for biochemical compounds that may serve 
as antidiabetic treatments. Our study examines the 
antidiabetic potential of Swietenia mahagoni, a tree 
found almost everywhere in Indonesia. Studies report 
that Indian Swietenia mahagoni has antioxidative and 
antidiabetic activities in streptozotocin-induced rats 
(Panda et al. 2010). De et al. (2010) also suggested 
that Indian Swietenia mahagoni is a good candidate 
for antidiabetic medicine. However, no antidiabetic 
product has yet been produces using Swietenia 
mahagoni seed. The Swietenia mahagoni seeds 
used in this study were obtained from Leuwiliang 
Bogor, Indonesia. Little is known about the 
potency of Swietenia mahagoni, but we know that 
bioactive compounds found in plants may depend 
on the location where they grow. This study of 
the antidiabetic properties of Swietenia mahagoni 
will also provide information specific to plants 
grown in Leuwiliang Bogor, Indonesia. This study 
is a preliminary study to explore the potential for 
producing an antidiabetic product using Swietenia 
mahagoni seed. The objective of this study was to 
analyse the inhibitory activity of  Swietenia mahagoni 
seed extracts to in vitro alpha-glucosidase and the in 
vivo hypoglycemic activity of the extract in sucrose-
induced hyperglycemic rats.
MATERIALS AND METHODS
 Materials. Swietenia mahagoni seeds were 
harvested from the wild in Leuwiliang, Bogor, 
Indonesia. Sampling was done using WHO procedure 
(2000). The seeds were first dried at 50 oC, then were 
ground and filtered with 40 mm mesh. A total of 40 
male Sprague-Dawley rats were used in this study. 
The rats were obtained from Animal Laboratory Unit, 
Faculty of Veterinary Medicine, Bogor Agricultural 
University, Indonesia.
 Swietenia mahagoni Seeds Extraction. 
Extraction was carried out using two methods, 
maceration and reflux. We also used two solvents, 
aquadest and ethanol. This resulted in a total of four 
extracts: (i) aquaeus-maceration extract, (ii) ethanol-
maceration extract, (iii) aquaeus-reflux extract, (iv) 
ethanol-reflux extract (Figure 1). The maceration 
method was as follows: Swietenia mahagoni seeds 
were dried and ground into powder, which was mixed 
with solvent (1:5) for 24 h, followed by filtration. 
The maceration was repeated three times with the 
same solvent. All of the filtrate was then evaporated 
using vacuum evaporator. Maceration using aquadest 
was carried out using aquadest at 80-90 oC. Reflux 
extraction was carried out over 6 h, using a 1:5 
proportion of sample to solvent, then left overnight. 
The resulting filtrate was then filtered, and evaporated 
using vacuum evaporator. All of the resulting four 
extracts were then analyzed for phytochemical 
compounds, including alkaloids, phenols, flavonoids, 
etc. (Harborne 1987).
 In vitro–Inhibitory Activity of Extracts on 
α-Glucosidase. We created an enzyme solution 
consisting of 1.0 mg a-glucosidase in 100 mL 
phosphate buffer (pH 7.0) containing 200 mg bovine 
serum albumin (BSA). One mL of this enzyme 
solution was then diluted 25 times with phosphate 
buffer. The reaction solution consisted of 250 µL 20 
mM p-nitrophenyl a-D-glucopiranose (as a subtrate), 
490 µL phosphate buffer, 10 µL extract, and 10 µL 
DMSO. The reaction solution was then incubated in 
water bath at 37 oC for 5 min, then amended with 250 
µL enzyme solution, followed by incubation again 
for 15 min. The reaction was then stopped via the 
addition of 1000 µL 200 mM sodium carbonate. The 
absorbancy of the reaction result was measured at l 
= 410 nm. Percent inhibition was then calculated as 
follows: [(C-S)/C] x 100%, S = sample absorbancy 
(S1-S0), S1 = sample absorbancy with enzyme, S0 = 
sample absorbancy without enzyme, and C = control 
absorbancy (DMSO) without sample. 
 In vivo-Hypoglycemic Activity of Extract on 
Sucrose-Induced Hyperglycemic Rats. Rat care 
and experimental procedures in this study were in 
accordance with Ethical Approval Letter No. 14-
2013 IPB from Animal Care and Use Committe, 
Bogor Agricultural University. A total of 40 male 
Sprague-Dawley rats were used for this study.  They 
were divided into eight groups: a negative control 
group, a positive control group, and five groups 
that were treated with the extract, that showed the 
highest inhibitory activity on alpha-glucosidase (that 
is ethanol-maceration extract of Swietenia mahagoni 
Aquaeous-maceration extract Ethanol-maceration extract
Aquaeous-reflux extract Ethanol-reflux extract
Figure 1. Swietenia mahagoni seed extracts.
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seed) at dose 100, 200, 300, 400, and 500 mg/kgBW, 
and an acarbose (4.5 mg/kgBW) treated group. 
All the rats were made to fast for 10 h, then blood 
glucose level were measured to serve as the 0 minute 
baseline level. The rats were then given an orally 
administrated dose of aquadest (negative control and 
positive control groups), ethanol maceration extract 
of Swietenia mahagoni seed (extract treated groups) 
at dose 100, 200, 300, 400, and 500 mg/kgBW, or 
acarbose (acarbose treated group). After 10 min, 
all of rats were given an orally administrated 1 mL 
90% sucrose, except for the negative control group. 
The negative control group was given an orally 
administrated aquadest, as placebo. Blood glucose 
levels for the rats were then measured at 30, 60, 90, 
and 120 min after sucrose treatment. Blood glucose 
was measured using a Gluko Dr and strip kit.
RESULTS
 Phytochemical Characteristic of Swietenia 
mahagoni Seed Extract. Swietenia mahagoni 
seed extracts were showed in Figure 1. There are 
four extracts in this study, aquaeous-maceration, 
ethanol-maceration, aquaeous-reflux, and ethanol-
reflux extract. The characterization all of extracts 
were showed in Table 1, including water and 
ash content, as well as the extract yield, and the 
levels of phytochemical coumponds such as 
alkaloids, saponins, steroids, tannins, triterpenoids, 
hydroquinones, and flavonoids.
 The extract yield was highest using the maceration 
method and ethanol as a solvent (41.67%). The 
yield of aquaeous-maceration, aquaeous-reflux, and 
ethanol-reflux extract were 28.87, 14.95, and 21.61%, 
respectively. All four types of Swietenia mahagoni 
seed extracts showed a different composition of 
alkaloids, saponins, steroids, tannins, triterpenoids, 
and hydroquinones in variation. The total flavonoid 
content (in % with quercetin) was highest in the 
ethanol-maceration extract (0.706%).  The total 
flavonoid content (in % with quercetin) of aquaeous-
maceration, aquaeous-reflux, and ethanol-reflux 
extract were about 0.2% each (Table 1).
 Alpha-Glucosidase Inhibitory Activity of 
Swietenia mahagoni Extract. The inhibitory effect 
of Swietenia mahagoni extracts to a-glucosidase is 
shown in Table 2. The ethanol-maceration extract 
showed the highest inhibitory activity, measured 
18.647 percent inhibition at 100 ppm. The results 
for the other extracts were lower; ethanol-reflux 
extract (14.313), followed by aquaeos -reflux extract 
(5.309), and aquaeous-maceration extract (4.376). 
Based on these results and on the flavonoid content 
found in the extract (Table 1), the ethanol-maceration 
extract showed the greatest promise as an antidiabetic 
agent. Therefore, the hypoglycemic effect analysis 
of Swietenia mahagoni seed extract was carried out 
using only the ethanol-maceration  extract.
 Hypoglycemic Activity of Swietenia mahagoni 
Extract in Sucrose-Induced Hyperglycemic 
Rats. The results of hypoglycemic effect analysis 
of ethanol-maceration extract in Sprague-Dawley 
rats at dose 100, 200, 300, 400, and 500 mg/kgBW 
Table 1. The characteristic of Swietenia mahagoni seed extract
Parameter Aqueos maceration extract
Ethanol maceration 
extract
Aqueos reflux 
extract
Ethanol reflux 
extract
Water content
Ash content
Acid-insoluble ash content
Yield (%)
Organoleptic:    Form
                          Smell
                          Colour
Phytochemistry:
        Alkaloid:    Wegner
                           Meyer 
                           Dragendorf
        Steroid
        Tannin
        Saponin
        Triterpenoid
        Hidroquinone
              13.58
                5.42
                0.35
              28.87
powder
specific
brown
negative
positive
negative
positive
negative
positive
 positive
negative
                 2.22
                 2.48
                 0.12
               41.67
powder
specific
brown
positive
positive
negative
negative
negative
positive
positive
positive
           9.57
           3.26
           0.31
         14.95
powder
specific
brown
positive
negative
negative
positive
negative
positive
negative
negative
           2.88
           2.23
           0.21
         21.61
powder
specific
brown
negative
negative
negative
negative
negative
positive
positive
negative
Total flavonoid : quersetin % (w/w) 0.267 0.706 0.297 0.268
Table 2. α-glukosidase inhibitory activity of Swietenia mahagoni 
seed extract (at 100 ppm extract)
Swietenia mahagoni seed extract % Inhibition
Aquaeos maceration
Ethanol maceration
Aquaeos reflux
Ethanol reflux
4.376 + 0.192a
18.647 + 3.864b
5.309 + 0.514a
14.313 + 3.522b
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are shown in Figure 2. The negative control group 
showed normal blood glucose levels at 0, 30, 60, 
90, and 120 min. The blood glucose levels of the 
positive control group which received 90% sucrose 
solution without S. mahogoni seed extract increased 
to 150 mg/dL at 30 min after sucrose treatment. 
The blood glucose levels peaked (170 mg/dL) at 60 
min, and then decreased at 90 min,  reaching normal 
levels 120 min after sucrose solution treatment. The 
positive control group were hyperglycemic at testing 
intervals 30 and 60 min after receiving sucrose 
solution. The rats in the groups that were treated 
with sucrose solution and Swietenia mahagoni seed 
extract at all dose from 100 through 500 mg/kgBW 
showed slightly increased but normal blood glucose 
levels at the 30 and 60 min test time, with decreased 
(but normal) levels at min 90 and 120. All of the 
groups treated with Swietenia mahagoni seed extract 
exhibited blood glucose levels within normal range 
during the entire 120 min (Figure 2).  
DISCUSSION
 
 Swietenia mahagoni seed extract displayed 
the presence of bioactive compounds, such as 
alkaloids, steroids, tannins, saponins, triterpenoids, 
hidroquinons, and flavonoids. All of these bioactive 
compounds possess certain physiological functions. 
To determine if any of the functions might be 
antidiabetic, we tested for both a-glucosidase 
inhibition and hypoglycemic effects of Swietenia 
mahagoni seed extract. An extract derived using 
ethanol solvent and the maceration method showed 
the best results, compared to extracts using other 
methods and solvents, in term of highest yield 
and flavonoid contents. In vitro analysis indicated 
that the ethanolic-maceration extract also showed 
the greatest a-glucosidase inhibition activity than 
the other extracts. This suggested that levels of 
a-glucosidase inhibitors may be correlated with 
alkaloid, triterpenoid, and flavonoid levels in the 
Swietenia mahagoni seed extract (Table 1). Benala 
et al. (2010) reported that naturally abundant 
antioxidant compounds have received considerable 
attention as potential a-glucosidase inhibitors. 
Alkaloids (Patel & Mishra 2012), triterpenes (Lai 
et al. 2012), and flavonoids (Wang et al. 2010) have 
all been reported to exhibit a-glucosidase inhibitor 
properties.
 In vivo  analysis showed that Swietenia 
mahagoni seed extract, especially ethanolic extract, 
has a hypoglycemic effect in sucrose-induced 
hyperglycemic rats. This is indicated by the fact that 
blood glucose measurement in all of the rats treated 
with Swietenia mahagoni seed extract never reached 
hyperglycemic levels during the 120 min observation 
period for 120 min. Normal blood glucose levels 
for rats range between 90-142 mg/dL (Kim et al. 
2006), or 99-127 mg/dL (Gulfraz et al. 2007). The 
positive control group, which received the 90% 
sucrose solution without Swietenia mahogoni seed 
extract treatment, exhibited hyperglycemic blood 
glucose levels at 30th and 60th min after sucrose 
treatment. This hyperglycemic condition indicates 
increased absorption of glucose in the small intestine 
as a result of sucrose hydrolysis. In contrast, rats 
treated with sucrose and with Swietenia mahagoni 
seed extract were able to suppress this process 
and maintain normal blood glucose measurement. 
These results suggest that Swietenia mahagoni seed 
ethanolic-maceration extract, works in a similar way 
as acarbose treatment to lower blood glucose level. 
The Swietenia mahagoni seed ethanolic-maceration 
extract may inhibit the activity of a-glucosidase in 
the small intestine as showed at in vitro analysis, 
delaying sucrose digestion, and thus reducing the rate 
of glucose absorption. Consequently, normal blood 
glucose level can be maintained despite treatment 
with a dose of sucrose that would ordinarily cause a 
hyperglycemic condition.
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Figure 2. Blood glucose level of rats. The positive control group 
(hyperglycemic) showed the highest blood glucose 
level, especially at 30 and 60 min after oral treatment 
with sucrose.  Rats treated with ethanol Swietenia 
mahagoni seed extract (100, 200, 300, 400, and 500 
mg/kgBW) showed lower blood glucose levels than 
rats in the positive control group. 
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 Diabetes is a common metabolic disease 
characterized by abnormall high plasma glucose levels 
(hyperglycemia), leading to major complications, 
such as diabetic neuropathy, retinopathy, and 
cardiovascular diseases (Kumar et al. 2011). 
Hyperglycemia is a metabolic disorder primarily 
characterized by a disorder of the β-cells, relative 
insulin deficiency, and an abnormal rise in blood 
glucose, right after a meal (Kwon et al. 2007).  One 
effective strategy to manage diabetes mellitus, is to 
decrease postpandrial hyperglycemia by retarding 
the absorbtion of glucose. This is achieved by 
inhibition of carbohydrate hydrolyzing enzymes, 
such as a-glucosidase and a-amylase, in the digestive 
organs (Kumar et al. 2011). a-Glucosidase is the 
key enzyme catalyzing the final step in the digestive 
process of carbohydrates. Hence, a-glucosidase 
inhibitors can retard the liberation of d-glucose from 
dietary complex carbohydrates, and so delay glucose 
absorption in the small intestine, resulting in reduced 
postpandrial plasma glucose levels and suppression 
of postpandrial hyperglycemia (PPHG). PPHG is a 
major risk factor for diabetic vascular complications 
leading to disability and mortality in diabetics 
(Shihabudeen et al. 2011). As reported by Bischoff 
(1995) a-glucosidase inhibitors via competitive and 
reversible inhibition of intestinal a-glucosidases, 
delay carbohydrate digestion, prolongs overall 
carbohydrate digestion time, and thus reduces the rate 
of glucose absorption. Casirola and Ferraris (2006) 
also reported that one potential mechanism by which 
a-glucosidase inhibitors blunt postpandrial glycemic 
spikes and lower fasting blood glucose concentration 
is by preventing carbohydrate-induced increases in 
intestinal sugar transport. Sustained reduction in 
hyperglycemia will decrease the risk of developing 
microvascular complications and most likely will 
reduce the risk associated with microvascular 
complications (Tas et al. 2005).  In animal subjects, 
some researches show that a low-carbohydrate diet 
supplemented with acarbose-a-glucosidase inhibitor 
was an effective means of decreasing exogenous 
insulin dependence and improving glycemic control 
in cats diabetes mellitus (Mazzaferro et al. 2003).  
 This study, both in vitro and in vivo, concluded 
that Swietenia mahagoni seed ethanolic-maceration 
extract has a-glucosidase inhibitory and hypoglycemic 
effects. The results suggest that the extract should be 
proposed as a potential antidiabetic treatment that 
lowers blood glucose, via inhibition of a-glucosidase. 
Raptis and Dimitriadis (2001) described various 
mechanisms by which oral hypoglycemic agents 
may work: as a-glucosidase inhibitors, insulin 
secretagogues, and insulin sensitizers. These and 
other potential antidiabetic mechanisms of Swietenia 
mahagoni seed extract as an antidiabetic agent still 
remain to be elucidated in experimental studies 
of diabetic rats, with observation of insulin level, 
antioxidant status, glycogen content in liver and 
muscle, as well as the number and condition of beta 
cells in Langerhans islet of pancreatic tissues, in 
addition to blood glucose level.
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